This led to the creation of a Her-DTX-NPs formulation that enables the sustained, controlled, and precise transportation of docetaxel specifically to breast cancer cells.176 This drug delivery system displayed improved stealth properties and cellular uptake efficiency, and was also proved to be more cytotoxic to HER2-overexpressing cancer cells. The gene discussed is ERBB2; the disease is breast cancer.